Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post Pounce System Use
Portfolio Pulse from Benzinga Newsdesk
Surmodics, Inc. announced promising early results from a subset analysis of 60 patients with limb ischemia, showing a 96.8% success rate in procedural flow restoration using the Pounce System. The results were presented at the 36th Annual TCT Symposium.
October 30, 2024 | 6:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surmodics reported a 96.8% success rate in restoring blood flow in limb ischemia patients using its Pounce System, with 81.7% of patients not needing further treatment. This positive outcome was shared at a major medical symposium.
The high success rate of the Pounce System in treating limb ischemia, as presented at a significant medical symposium, is likely to positively impact Surmodics' stock. The results demonstrate the effectiveness of their product, potentially increasing investor confidence and interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100